JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB230362

I-BET151, pan-BET family inhibitor

Be the first to review this product! Submit a review

|

(0 Publication)

MW 415.4 Da, Purity >98%. I-BET151 is an isoxazole class pan-BET family inhibitor, blocking BRD2, BRD3 and BRD4 with IC50 values of 0.5, 0.25 and 0.79 μM, respectively. Specifically, I-BET151 induces apoptosis via reduced expression of BCL2 or triggers G0/G1 cell cycle arrest in MLL-fusion cell lines.

View Alternative Names

(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, 1,8-cineole 2-exo-monooxygenase, 1B07_HUMAN, 5''-cyclic phosphodiesterase 4B, AS, Albendazole monooxygenase, Albendazole sulfoxidase, B-4901, B-7 alpha chain, BRD 6, BRD2_HUMAN, BRD3_HUMAN, BRD4-NUT FUSION, BRD4-NUT fusion oncoprotein, BRD4_HUMAN, BRDT protein, BRDT_HUMAN, Beta-interferon, Bromodomain containing 2, Bromodomain containing 3, Bromodomain containing 4, Bromodomain testis specific, Bromodomain testis-specific protein, Bromodomain-containing protein 2, Bromodomain-containing protein 3, Bromodomain-containing protein 4, CAP, CBP_HUMAN, CP2C9_HUMAN, CP33, CP34, CP3A4_HUMAN, CPC9, CREB-binding protein, CT9, CYP2C, CYP2C10, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIC9, CYPIIIA3, CYPIIIA4, Cancer/testis antigen 9, Cyclic AMP responsive enhancer binding protein, Cytochrome P-450MP, Cytochrome P450 2C9, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 NF-25, Cytochrome P450 PB-1, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 2, subfamily C, polypeptide 9, Cytochrome P450-PCN1, D6S113E, DKFZp686F2182, DKFZp686N0336, DPDE4, FLJ31942, FSH, FSRG1, Female sterile homeotic related gene 1, Female sterile homeotic related gene 1, mouse, homolog of, Fibroblast interferon, Glucocorticoid inducible P450, HC class I antigen SHCHA, HLA class I histocompatibility antigen, HLA class I histocompatibility antigen, B alpha chain, HLA-B histocompatibility type, HLP, HUNK1, HUNKI, IFB, IFF, IFN-beta, IFNB 1, IFNB_HUMAN, Interferon beta, Interferon beta 1 fibroblast, Interferon beta precursor, KAT3A, KIAA0043, KIAA9001, MCAP, MGC126529, MGC126680, MGC149605, MGC88320, MGC96956, MHC Class I HLA heavy chain, MHC HLA-B cell surface glycoprotein, MHC HLA-B transmembrane glycoprotein, MHC class 1 antigen, MHC class I antigen HLA-B alpha chain, MHC class I antigen HLA-B heavy chain, MHC class I molecule, MHC class I-antigen B*7, Microsomal monooxygenase, Mitotic chromosome-associated protein, NAT, NF 25, Nifedipine oxidase, O27.1.1, ORFX, OTTHUMP00000010652, OTTHUMP00000010653, OTTHUMP00000010654, OTTHUMP00000010656, OTTHUMP00000020135, OTTHUMP00000232365, Open reading frame X, P450 III steroid inducible, P450 MP, P450 PB 1, P450 PCN1, P450, family III, P450C3, P450IIC9, PDE IVB, PDE32, PDE4B5, PDE4B_HUMAN, Phosphodiesterase 4B, Phosphodiesterase 4B cAMP specific, Phosphodiesterase 4B, cAMP specific (phosphodiesterase E4 dunce homolog, Drosophila), Protein HUNK1, Quinine 3-monooxygenase, RING3, RING3 PROTEIN, RING3 like gene, RING3-like protein, RING3L, RNF3, RSTS, RTS, Really interesting new gene 3 protein, Rubinstein Taybi syndrome, S-mephenytoin 4-hydroxylase, SPDA1, Taurochenodeoxycholate 6-alpha-hydroxylase, Testis specific bromodomain protein, Xenobiotic monooxygenase, cAMP-specific 3'', cAMP-specific 3',5'-cyclic phosphodiesterase 4B, cAMP-specific phosphodiesterase-4 B isoform, chromosome associated protein, cytochrome P-450 S-mephenytoin 4-hydroxylase, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, dunce-like phosphodiesterase E4, flavoprotein-linked monooxygenase, leukocyte antigen class I-B, major histocompatibility complex, class I, B

1 Images
Chemical Structure - I-BET151, pan-BET family inhibitor (AB230362)
  • Chemical Structure

Lab

Chemical Structure - I-BET151, pan-BET family inhibitor (AB230362)

2D chemical structure image of ab230362, I-BET151, pan-BET family inhibitor

Key facts

CAS number

1300031-49-5

Purity

>98%

Form

Solid

form

Molecular weight

415.4 Da

Molecular formula

C<sub>2</sub><sub>3</sub>H<sub>2</sub><sub>1</sub>N<sub>5</sub>O<sub>3</sub>

PubChem

52912189

Nature

Synthetic

Solubility

DMSO (100 mM)

Ethanol (100 mM)

Biochemical name

7-(3,5-Dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-(pyridin-2-yl)ethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one

Biological description

I-BET151 is an isoxazole class pan-BET family inhibitor, blocking BRD2, BRD3 and BRD4 with IC50 values of 0.5, 0.25 and 0.79 μM, respectively. Specifically, I-BET151 induces apoptosis via reduced expression of BCL2 or triggers G0/G1 cell cycle arrest in MLL-fusion cell lines.

Canonical smiles

CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=N5)OC

Isomeric smiles

CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)[C@H](C)C5=CC=CC=N5)OC

InChi

InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1

InChiKey

VUVUVNZRUGEAHB-CYBMUJFWSA-N

IUPAC Name

7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1R)-1-pyridin-2-ylethyl]-3H-imidazo[4,5-c]quinolin-2-one

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CREBBP also known as CBP is a transcriptional coactivator with intrinsic histone acetyltransferase activity essential for regulating gene expression. Its molecular mass is approximately 265 kDa. CREBBP is expressed in various tissues including the brain heart and lungs and acts as a scaffold for other transcription factors modulating their activity. Interferon beta (IFN-β) a type of cytokine is an important mediator of the immune response. Cytochrome P450 3A4 frequently known as CYP3A4 is a critical enzyme responsible for the metabolism of many xenobiotics and is mainly expressed in the liver. BRD2 BRD3 and Brd4 part of the BET (bromodomain and extra-terminal domain) family act as transcriptional regulators. PDE4B is an enzyme involved in the breakdown of cAMP and HLA B a gene encoding an MHC class I molecule plays a significant role in immune function.
Biological function summary

CREBBP facilitates acetylation of histones influencing chromatin structure and gene transcription. It acts within a multifunctional protein complex involving histone deacetylases and methyltransferases interacting with other transcriptional regulators such as BRD4. CYP3A4 metabolizes various drugs aiding in detoxification processes. BRD proteins including BRD2 and BRD3 modulate transcription impacting cell cycle progression and inflammation. PDE4B regulates intracellular cAMP levels affecting signal transduction. Interferon beta acts by inducing the expression of IFN-stimulated genes controlling antiviral responses. HLA B is essential in immune surveillance presenting antigenic peptides to T cells.

Pathways

CREBBP is an integral part of the transcriptional regulation pathway where it influences the activity of other transcription factors like NF-kB. Its activity intersects with signaling pathways involving BRD proteins. CYP3A4 plays an important role in the metabolic pathway of drug detoxification and interacts with other P450 enzymes such as CYP2C9. BRD proteins including BRD4 are linked with the transcriptional pathway regulating genes associated with inflammation and cancer. PDE4B modulates signaling pathways involving cAMP influencing cellular responses. Interferon beta is part of the JAK-STAT signaling pathway important for antiviral defense. HLA B's role in antigen presentation ties it to immune response pathways particularly in adaptive immunity.

CREBBP mutations or dysfunctions associate with disorders like Rubinstein-Taybi Syndrome. Dysregulation in pathways involving CREBBP and BRD4 connects to cancer. Altered CYP3A4 activity impacts drug metabolism and is relevant in drug-induced liver injury and variability in drug efficacy. BRD2 and BRD3 abnormalities relate to cancer dynamics. PDE4B has implications in inflammatory diseases such as asthma. Interferon beta is significant in autoimmune disorders like multiple sclerosis where its modulation of immune responses impacts disease progression. HLA B association with autoimmune diseases like psoriasis involves antigen presentation and T cell activation illustrating its role in immune-mediated disorders.

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com